ArticlePediatric hematology and oncology2025

Why are Higher CD34+ Cell Doses Associated with Improved Outcomes among Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors - But Not for High-Risk Neuroblastoma?

Tristan E Knight et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.